Keywords
Mucorales
COVID-19
Mycoses
How to Cite
Abstract
During COVID-19 pandemic, fulminant deep fungal infection started emerging in India, known as Mucormycosis. This type of mucormycosis was termed as COVID-19 associated mucormycosis (CAM). These patients had previous history of COVID-19 infection. Such cases were mainly reported in immunocompromised patients such as patients with poorly controlled diabetes and chronic renal diseases etc. Rhinomaxillary mucormycosis is an aggressive, fulminant, fatal deep fungal infection of head and neck region. Early diagnosis and prompt treatment can reduce the mortality and morbidity associated with the disease; hence we present case series of rhinomaxillary mucormycosis to create awareness amongst dental surgeons.
References
Fürbringer P. [Observations on pulmonary mycosis in humansn]. Virchows Arch Path Anat. 1876;66:330-5. German. doi: 10.1007/BF01878266.
Hernández JL, Buckley CJ. Mucormycosis. 2022 Apr 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.
Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019 Mar;5(1):26. doi: 10.3390/jof5010026.
Centers for Disease Control and Prevention. Information for Healthcare Professionals about Mucormycosis. 2020 May 27 [cited 2021 Jun 19]. Available from: https://www.cdc.gov/fungal/diseases/mucormycosis/health-professionals.html.
Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses. 2014 Dec;57 Suppl 3:85-90. doi: 10.1111/myc.12243.
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102146. doi: 10.1016/j.dsx.2021.05.019.
Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6.ed. Philadelphia: Elsevier-Churchill Livingstone; 2005.
Chinn RYW, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: Relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun. 1982 Dec;38(3):1123-9. doi: 10.1128/iai.38.3.1123-1129.1982.
Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother. 2008 Feb;52(2):722-4. doi: 10.1128/AAC.01136-07.
Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest. 1984 Jul;74(1):150-60. doi: 10.1172/JCI111395.
Gartenberg G, Bottone EJ, Keusch GT, Weitzman I. Hospital-acquired Mucormycosis ( Rhizopus rhizopodiformis ) of skin and subcutaneous tissue . N Engl J Med. 1978 Nov 16;299(20):1115-8.
Mead JH, Lupton GP, Dillavou CL, Odom RB. Cutaneous Rhizopus infection. Occurrence as a postoperative complication associated with an elasticized adhesive dressing. JAMA. 1979 Jul;242(3):272-4. doi: 10.1001/jama.242.3.272.
Rajagopalan S. Serious infections in elderly patients with diabetes mellitus. 2005 Apr;40(7):990-6. doi: 10.1086/427690.
Lin E, Moua T, Limper AH. Pulmonary mucormycosis: clinical features and outcomes. Infection. 2017 Aug;45(4):443-8. doi: 10.1007/s15010-017-0991-6.
Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia. 2021 May;186(2):289-98. doi: 10.1007/s11046-021-00528-2.
Kanwar A, Jordan A, Olewiler S, Wehberg K, Cortes M, Jackson BR. A fatal case of rhizopus azygosporus pneumonia following covid-19. J Fungi (Basel). 2021 Feb;7(3):174. doi: 10.3390/jof7030174.
Nucci M, Barreiros G, Guimarães LF, Deriquehem VAS, Castiñeiras AC, Nouér SA. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. Mycoses. 2021 Feb;64(2):152-6. doi: 10.1111/myc.13225.
Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020 Oct;26(10):1395-9. doi: 10.1016/j.cmi.2020.06.025.
Posteraro B, Torelli R, Vella A, Leone PM, De Angelis G, De Carolis E, et al. Pan-echinocandin-resistant candida glabrata bloodstream infection complicating covid-19: A fatal case report. J Fungi (Basel). 2020 Sep;6(3):163. doi: 10.3390/jof6030163.
Meijer EFJ, Dofferhoand ASM, Meis JF, Hoiting O, Buil JB. Azole-resistant COVID-19-associated pulmonary aspergillosis in an immunocompetent host: a case report. J Fungi (Basel). 2020 Jun;6(2):79. doi: 10.3390/jof6020079.
Centers for Disease Control and Prevention. Fungal diseases. Diagnosis and testing of Mucormycosis. 2021 Jan 14 [cited 2021 Jun 20]. Available from: https://www.cdc.gov/fungal/diseases/mucormycosis/diagnosis.html.
Centers for Disease Control and Prevention. Fungal diseases. Treatment for Mucormycosis. 2021 Jan 14 [cited 2021 Jun 20]. Available from: https://www.cdc.gov/fungal/diseases/mucormycosis/treatment.html.
Losee JE, Selber J, Vega S, Hall C, Scott G, Serletti JM. Primary cutaneous mucormycosis: Guide to surgical management. Ann Plast Surg. 2002 Oct;49(4):385-90. doi: 10.1097/00000637-200210000-00009.
Sun H-Y, Singh N, Singh N, Sun H-Y. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis. 2011 Apr;11(4):301-11. doi: 10.1016/S1473-3099(10)70316-9.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2021 Sulem Ansari, Jayraj Malik, Anabelle Fernandes, Vaishali Keluskar, Shivayogi Charantimath
Downloads
